Komori
Revision of earnings forecasts4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Financial Results for the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated)

Reported consolidated results for the fiscal year ended March 2026. Net sales, operating profit, ordinary profit and net income attributable to owners of the parent all exceeded the previous fiscal year. The company also provided its full-year forecast for the fiscal year ending March 2027 and increased the fiscal year-end dividend for the fiscal year ended March 2026 from ¥23 to ¥25 per share.

Worth reading
73In focus
Scored from 4 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full year
Net Sales—→369,500million
+7.5%
Operating profit—→43,800million
+6.5%
Ordinary income—→46,100million
-3.9%
Profit attributable to owners of the parent—→34,500million
+0.7%
Net income per share—→152.68yen and sen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

In Japan, concerns remain over a shift toward cost-conscious consumer behavior due to rising prices, while expanded wage increases and capital investment and increased inbound demand are expected. Overseas, the forecast assumes uncertainty stemming from geopolitical risks. The company plans to pursue initiatives including the development of new products and collaboration with other companies.

Details and amount of extraordinary loss

Loss on disposal of fixed assets: ¥198 million; impairment loss: ¥43 million; valuation loss on investment securities: ¥1,229 million; valuation loss on shares of affiliated companies: ¥15 million; total extraordinary losses: ¥1,486 million

Previous-period resultsNet sales: ¥343,725 million; operating profit: ¥41,118 million; ordinary profit: ¥47,971 million; net income attributable to owners of the parent: ¥34,247 million; earnings per share: ¥151.56
Dividend forecast revisionThe fiscal year-end dividend per share for the fiscal year ended March 2026 was changed from ¥23 to ¥25. The full-year dividend forecast for the fiscal year ending March 2027 is ¥50 per share.
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → ¥369,500 million(+7.5%)
Operating profitNot disclosed → ¥43,800 million(+6.5%)
Ordinary incomeNot disclosed → ¥46,100 million(-3.9%)
Profit attributable to owners of the parentNot disclosed → ¥34,500 million(+0.7%)
Net income per shareNot disclosed → 152.68 yen and sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Previous-period resultsNet sales: ¥343,725 million; operating profit: ¥41,118 million; ordinary profit: ¥47,971 million; net income attributable to owners of the parent: ¥34,247 million; earnings per share: ¥151.56
Reason for the revisionIn Japan, concerns remain over a shift toward cost-conscious consumer behavior due to rising prices, while expanded wage increases and capital investment and increased inbound demand are expected. Overseas, the forecast assumes uncertainty stemming from geopolitical risks. The company plans to pursue initiatives including the development of new products and collaboration with other companies.
Details and amount of extraordinary lossLoss on disposal of fixed assets: ¥198 million; impairment loss: ¥43 million; valuation loss on investment securities: ¥1,229 million; valuation loss on shares of affiliated companies: ¥15 million; total extraordinary losses: ¥1,486 million
Dividend forecast revisionThe fiscal year-end dividend per share for the fiscal year ended March 2026 was changed from ¥23 to ¥25. The full-year dividend forecast for the fiscal year ending March 2027 is ¥50 per share.
Consolidated / non-consolidatedConsolidated
Items this document does not state (1)
Publication date of previous forecast

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

For the fiscal year ended March 2026, proposals for products suited to customer needs in Japan and overseas and increased inbound demand contributed to higher sales. Overseas, the consolidation of ユーヤンサン・インターナショナル and モノ also contributed to the increase in sales. Although the cost ratio rose, operating profit increased as a result of higher sales. For the fiscal year ending March 2027, the company plans to pursue initiatives including the development of new products and collaboration with other companies, based on assumptions of rising prices in Japan and geopolitical risks overseas.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated) | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori